Felzartamab in Late Antibody-Mediated Rejection

计划入组 22 人 · 首次发布于 2021 年 8 月 25 日

Daratumumab for Late Antibody-Mediated Rejection

计划入组 20 人 · 首次发布于 2025 年 7 月 23 日

Endothelial Microparticules and Antibody Mediated Rejection and Kidney Transplantation: Biomarker of Antibody-mediated Rejection in Kidney Transplantation

计划入组 249 人 · 首次发布于 2017 年 3 月 31 日

cell-mediated immunotherapy

AAV-mediated SaCas9-KKH

IG-7

Cambridge Antibody Technology

New Zealand

Latticon Antibody Therapeutics, Inc

United States

MiNK Therapeutics

United States

Imlifidase Demonstrates Superior Efficacy Over Plasmapheresis in Kidney Transplant Recipients with Antibody-Mediated Rejection

Biogen Initiates Phase 3 TRANSCEND Trial of Felzartamab for Late Antibody-Mediated Kidney Transplant Rejection

Phase 3 Trial of Clazakizumab Fails to Meet Primary Endpoint in Chronic Active Antibody-Mediated Kidney Transplant Rejection